Project Grant R43AI188776
Award Date 8/13/25
Completion Date 1/31/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $171,254 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Nimml Institute Inc., a 501(c)(3) non-profit research organization in Blacksburg, Virginia. The grant, effective from December 1, 2024 to November 30, 2026, aims to elucidate novel immunometabolic mechanisms that intercept bacterial toxin internalization and processing to suppress cell damage caused by Clostridioides difficile...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $511,553 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore. The grant funding will support the development of an oral immunotherapy using engineered probiotic yeast to deliver neutralizing antibodies against the Clostridioides difficile (C. diff) surface protein CWP84. This novel approach aims to reduce C. diff colonization and spore...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) is supporting research to develop a novel, water-soluble, cationic bolaamphiphile (CAB) platform nanocarrier complexed with an antisense oligonucleotide (ASO) targeting the essential C. difficile dnaE gene. The $426,875 award, which began on Jul 14, 2025 and runs through Jun 30, 2027, aims to advance this platform technology as a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $161,859 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Texas A&M University System Health Science Center (TAMU HSC) to conduct research on discovering novel antivirulence drug targets for Clostridioides difficile infection (CDI). The research aims to identify genetic mechanisms that regulate the production of virulence toxins by C. difficile, with the goal of finding...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $136,104 Project Grant to Tufts University School of Medicine. The grant, awarded on October 24, 2025, will support research to investigate the effect of Clostridioides difficile's (C. difficile) spatial distribution and toxin gene expression within the colon on disease severity. The research will utilize fluorescent reporter strains...
- This Project Grant award of $2,872,722 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the role of penicillin-binding proteins (PBPs) in the Clostridioides difficile life cycle and develop new PBP inhibitors to target C. difficile sporulation. The research aims to enhance the understanding of PBPs across bacterial species and provide new insights into the unique...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $754,446 to the University of Tennessee Health Science Center to develop novel microbiome-sparing antibacterial treatments for Clostridioides difficile infection (CDI). The key objectives are to: 1) optimize lead inhibitor compounds targeting the bacterial enzyme FABK to improve antimicrobial potency;...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $529,498 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Siolta Therapeutics Inc. for the development of a multispecies live biotherapeutic product (LBP) called STMC-105. The goal of this project is to create an FDA-approved therapy for the prevention of recurrent bacterial vaginosis (RBV) in women by enhancing the colonization of protective Lactobacillus bacteria and reducing...